michigan glp-1 nausea class action Ozempic Gastroparesis Lawsuit | Actions Lawyer Use of GLP-1 agonists prior

On the basis of current guidelines, GLP-1 RAs should be considered in patients with T2DM and CVD or CV risk factors

While some older GLP-1 agonists required daily dosing (such as liraglutide), the once-weekly formulations now dominate due to their ease of use and sustained effect

Understanding your genetic profile empowers personalized decisions about alcohol consumption during GLP-1 therapy

For example, one study showed that in people with type 2 diabetes, treatment with semaglutide (1 mg weekly) causes an average loss of about 6% of body weight over 40 weeks, while treatment with tirzepatide (15 mg/week) leads to an 11% weight loss in this population